Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Virology|October 11, 2013
Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virusDror Kolodkin-Gal, Sandrine L Hulot, Birgit Korioth-Schmitz, et al.
Journal of Virology|November 13, 2009
Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeysAravind Basavapathruni, Wendy W Yeh, Rory T Coffey, et al.
Clinical Therapeutics|May 5, 2018
A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese ParticipantsTommy Tsang Cheung, Joanne Wing Yan Chiu, Man Fung Yuen, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 16, 2023
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19Jennifer E Sager, Asma El-Zailik, Julie Passarell, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Journal of Virology|April 2, 2010
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysWendy W Yeh, Ishita Rahman, Peter Hraber, et al.
Pageof 5